ATDC Function in Human Pancreatic Adenocarcinoma
ATDC 在人胰腺腺癌中的功能
基本信息
- 批准号:7920797
- 负责人:
- 金额:$ 31.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:ATM geneAdenocarcinomaApoptosisAtaxia TelangiectasiaCell Cycle CheckpointCell NucleusDNA DamageDNA RepairDefectDiagnosisDiseaseGenesGenetic TranscriptionGrowthHereditary DiseaseHumanIn VitroIonizing radiationLeadLinkMalignant neoplasm of pancreasMediatingMediator of activation proteinModalityMolecularNeoplasm MetastasisNuclearPancreatic AdenocarcinomaPathway interactionsPatientsProtein FamilyProteinsResistanceRoleSignal PathwaySignal TransductionSiteStimulation of Cell ProliferationTherapeuticTissuesXenograft Modelbasebeta catenincancer cellchemotherapeutic agentchemotherapygemcitabineimprovedin vivonanovectornew therapeutic targetnoveloverexpressionpancreas xenograftpancreatic neoplasmpre-clinicalpublic health relevanceresponsesmall hairpin RNAtherapy resistanttraffickingtumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Pancreatic cancer is a deadly disease characterized by late diagnosis, aggressive invasion of surrounding tissues, early metastasis, and resistance to therapy. There is an urgent need to develop highly effective, mechanism-based therapies to improve survival in these patients. We have recently found that the majority of human pancreatic adenocarcinomas specifically over-express the gene for Ataxia-Telangiectasia Group D Associated (ATDC). The ATDC gene was initially described in association with the genetic disorder ataxia-telangiectasia (AT) but was later found not to be the gene responsible for that disorder, and it's function remained unknown. We have identified ATDC as a novel DNA damage response gene that confers a survival advantage to pancreatic cancer cells when exposed to chemotherapy. We have shown that following DNA damage, ATDC traffics to the nucleus, is phosphorylated in response to gemcitabine and localizes to DNA repair foci. Loss of ATDC results in increased sensitivity to gemcitabine-induced apoptosis and a defect in downstream cell cycle checkpoint signaling. We have also found that high levels of ATDC confer a growth advantage to pancreatic cancer cells both in vitro and in vivo. The ATDC-mediated stimulation of cell proliferation may be due to enhancement of the beta-catenin pathway since overexpression of ATDC increases beta-catenin mediated transcription. We demonstrate that ATDC interacts with the HIT family protein HINT1, a negative regulator of the beta-catenin pathway, and we hypthesize that ATDC stimulates beta-catenin-mediated proliferation by sequestering HINT1. In this proposal, we will explore the following specific aims: 1) To examine the role of ATDC in the ATR-mediated DNA damage response. 2) To assess if ATDC's tumor promoting ability is linked to stimulation of the beta-catenin pathway through interactions with the HIT1 family protein HINT1. 3) To analyze the efficacy of targeting ATDC as a therapeutic modality in a pre-clinical, primary human pancreatic cancer orthotopic xenograft model. PUBLIC HEALTH RELEVANCE: We propose that ATDC is a promising novel therapeutic target in pancreatic cancer because it's inactivation may lead to both reduced tumor growth and sensitization to chemotherapy.
描述(由申请人提供):胰腺癌是一种致命的疾病,其特征是诊断较晚,侵袭周围组织,早期转移和治疗抵抗。迫切需要开发高效的、基于机制的治疗方法来提高这些患者的生存率。我们最近发现,大多数人胰腺癌特异性过表达共济失调-毛细血管扩张D组相关(ATDC)基因。ATDC基因最初被描述为与遗传性疾病共济失调-毛细血管扩张症(AT)相关,但后来发现不是导致该疾病的基因,其功能仍然未知。我们已经确定ATDC作为一种新的DNA损伤反应基因,赋予胰腺癌细胞暴露于化疗时的生存优势。我们已经表明,在DNA损伤后,ATDC运输到细胞核,响应于吉西他滨被磷酸化并定位于DNA修复灶。ATDC的缺失导致对吉西他滨诱导的细胞凋亡的敏感性增加和下游细胞周期检查点信号传导的缺陷。我们还发现,高水平的ATDC在体外和体内都赋予胰腺癌细胞生长优势。ATDC介导的细胞增殖刺激可能是由于β-连环蛋白途径的增强,因为ATDC的过表达增加了β-连环蛋白介导的转录。我们证明了ATDC与HIT家族蛋白HINT 1(β-连环蛋白通路的负调节因子)相互作用,我们推测ATDC通过隔离HINT 1刺激β-连环蛋白介导的增殖。本研究的主要目的是:1)研究ATDC在ATR介导的DNA损伤反应中的作用。2)评估ATDC的肿瘤促进能力是否与通过与HIT 1家族蛋白HINT 1相互作用刺激β-连环蛋白通路有关。3)在临床前原发性人胰腺癌原位异种移植模型中分析靶向ATDC作为治疗方式的疗效。公共卫生相关性:我们认为ATDC是胰腺癌治疗的一个有前途的新靶点,因为它的失活可能导致肿瘤生长减少和对化疗敏感。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DIANE M SIMEONE其他文献
DIANE M SIMEONE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DIANE M SIMEONE', 18)}}的其他基金
Biomarker Validation in Pancreatic Cystic Neoplasms
胰腺囊性肿瘤的生物标志物验证
- 批准号:
10722347 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
HR 缺陷型胰腺癌中的 POLQ 综合致死率
- 批准号:
10218126 - 财政年份:2020
- 资助金额:
$ 31.82万 - 项目类别:
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
HR 缺陷型胰腺癌中的 POLQ 综合致死率
- 批准号:
10442427 - 财政年份:2020
- 资助金额:
$ 31.82万 - 项目类别:
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
HR 缺陷型胰腺癌中的 POLQ 综合致死率
- 批准号:
10656484 - 财政年份:2020
- 资助金额:
$ 31.82万 - 项目类别:
2015 Pancreatic Diseases Gordon Research Conference
2015年胰腺疾病戈登研究会议
- 批准号:
8970783 - 财政年份:2015
- 资助金额:
$ 31.82万 - 项目类别:
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis
项目3:lncRNA SNHG1和ATG7在基底亚型肌侵袭性膀胱肿瘤发生中的作用
- 批准号:
10661067 - 财政年份:2013
- 资助金额:
$ 31.82万 - 项目类别:
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis
项目3:lncRNA SNHG1和ATG7在基底亚型肌侵袭性膀胱肿瘤发生中的作用
- 批准号:
10229414 - 财政年份:2013
- 资助金额:
$ 31.82万 - 项目类别:
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis
项目3:lncRNA SNHG1和ATG7在基底亚型肌侵袭性膀胱肿瘤发生中的作用
- 批准号:
10455731 - 财政年份:2013
- 资助金额:
$ 31.82万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:














{{item.name}}会员




